Combioxin
SA, a clinical-stage biotechnology company focused on the development of
innovative treatments for severe and resistant infections, announced today that
first-in-human clinical results with
CAL02 in severe pneumonia patients in ICU was presented during
the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in
Paris, France. A recording is available:
Presentation
details were as follows:
- Session: Management of patients with sepsis
- Title: Adjunctive intravenous anti-toxin treatment with CAL02 in severe acute communityacquired pneumonia due to Streptococcus pneumoniae. A first-in-man, multicentre, double-blind, placebo-controlled study
- Presenter: Pierre-François Laterre, Cliniques universitaires Saint-Luc, Université catholique de Louvain (UCL), Brussels, Belgium Date: Wednesday, October 24, 2018 Time: 10:10 AM Location: Barcelona Hall, Palais des Congrès, Paris, France Presentation number: 0995
No comments:
Post a Comment
Pharmaceutical Microbiology Resources